Hollis, Robert L.
Thomson, John P.
van Baal, Juliette
Ilenkovan, Narthana
Churchman, Michael
van de Vijver, Koen
Dijk, Frederike
Meynert, Alison M.
Bartos, Clare
Rye, Tzyvia
Croy, Ian
Diana, Patricia
van Gent, Mignon
Creedon, Helen
Nirsimloo, Rachel
Lok, Christianne
Gourley, Charlie
Herrington, C. Simon
Funding for this research was provided by:
Target Ovarian Cancer (Edinburgh-CG19)
IGC Langmuir Talent Fellowship (RLH-22)
Cancer Research UK
Hanarth Foundation
Medical Research Council
Article History
Received: 30 November 2022
Accepted: 4 May 2023
First Online: 11 May 2023
Competing interests
: RLH: consultancy fees from GlaxoSmithKline and DeciBio. CG: research funding from AstraZeneca, MSD, Novartis, Aprea, Nucana, GSK, BerGen Bio, Medannexin, Artios; honoraria/consultancy fees from AstraZeneca, MSD, GSK, Clovis, Chugai, Cor2Ed, Takeda, Eisai, Peer Voice; named on issued/pending patents related to predicting treatment response in ovarian cancer outside the scope of the work described here. All other authors declare no conflicts of interest.